Michael E Ray

Summary

Affiliation: University of Michigan
Country: USA

Publications

  1. ncbi Family history of prostate cancer and relapse after definitive external beam radiation therapy
    Michael E Ray
    Department of Radiation Oncology, University of Michigan Medical School, Ann Arbor, MI, USA
    Int J Radiat Oncol Biol Phys 57:371-6. 2003
  2. ncbi PSA nadir predicts biochemical and distant failures after external beam radiotherapy for prostate cancer: a multi-institutional analysis
    Michael E Ray
    Department of Radiation Oncology, University of Michigan, Ann Arbor, MI 48109 0010, USA
    Int J Radiat Oncol Biol Phys 64:1140-50. 2006
  3. ncbi Clonality of sarcomatous and carcinomatous elements in sarcomatoid carcinoma of the prostate
    Michael E Ray
    Department of Radiation Oncology, University of Michigan, Ann Arbor, Michigan, USA
    Urology 67:423.e5-423.e8. 2006
  4. ncbi E-cadherin protein expression predicts prostate cancer salvage radiotherapy outcomes
    Michael E Ray
    Department of Radiation Oncology, Comprehensive Cancer Center, University of Michigan, Ann Arbor, Michigan 48109 0010, USA
    J Urol 176:1409-14; discussion 1414. 2006
  5. ncbi Nadir prostate-specific antigen within 12 months after radiotherapy predicts biochemical and distant failure
    Michael E Ray
    Department of Radiation Oncology, University of Michigan Medical Center, Ann Arbor, Michigan 48109 0010, USA
    Urology 68:1257-62. 2006
  6. ncbi Percent positive biopsy cores as a prognostic factor for prostate cancer treated with external beam radiation
    Aaron C Spalding
    Department of Radiation Oncology, University of Michigan Medical School, Ann Arbor, Michigan 48109, USA
    Urology 69:936-40. 2007
  7. ncbi Long-term outcomes after radiotherapy for retroperitoneal and deep truncal sarcoma
    Mary Feng
    Department of Radiation Oncology, University of Michigan Medical School, Ann Arbor, MI, USA
    Int J Radiat Oncol Biol Phys 69:103-10. 2007
  8. ncbi Inhibition of mTOR radiosensitizes soft tissue sarcoma and tumor vasculature
    James D Murphy
    Department of Radiation Oncology, University of Michigan, Ann Arbor, Michigan 48109 5010, USA
    Clin Cancer Res 15:589-96. 2009
  9. ncbi No effect of statins on biochemical outcomes after radiotherapy for localized prostate cancer
    Daniel E Soto
    Department of Radiation Oncology, University of Michigan, Ann Arbor, Michigan, USA
    Urology 73:158-62. 2009
  10. ncbi Randomized phase II trial of urethral sparing intensity modulated radiation therapy in low-risk prostate cancer: implications for focal therapy
    Jeffrey Vainshtein
    Department of Radiation Oncology, University of Michigan Hospital, Ann Arbor, MI, USA
    Radiat Oncol 7:82. 2012

Detail Information

Publications19

  1. ncbi Family history of prostate cancer and relapse after definitive external beam radiation therapy
    Michael E Ray
    Department of Radiation Oncology, University of Michigan Medical School, Ann Arbor, MI, USA
    Int J Radiat Oncol Biol Phys 57:371-6. 2003
    ..We examined our series of patients treated with definitive external beam radiation therapy to determine if a positive family history for prostate cancer is associated with better or worse outcome...
  2. ncbi PSA nadir predicts biochemical and distant failures after external beam radiotherapy for prostate cancer: a multi-institutional analysis
    Michael E Ray
    Department of Radiation Oncology, University of Michigan, Ann Arbor, MI 48109 0010, USA
    Int J Radiat Oncol Biol Phys 64:1140-50. 2006
    ....
  3. ncbi Clonality of sarcomatous and carcinomatous elements in sarcomatoid carcinoma of the prostate
    Michael E Ray
    Department of Radiation Oncology, University of Michigan, Ann Arbor, Michigan, USA
    Urology 67:423.e5-423.e8. 2006
    ....
  4. ncbi E-cadherin protein expression predicts prostate cancer salvage radiotherapy outcomes
    Michael E Ray
    Department of Radiation Oncology, Comprehensive Cancer Center, University of Michigan, Ann Arbor, Michigan 48109 0010, USA
    J Urol 176:1409-14; discussion 1414. 2006
    ..Altered expression of the adhesion molecule E-cadherin may be associated with the invasive and metastatic phenotype. We examined the relationship between E-cadherin expression and outcomes after salvage radiotherapy...
  5. ncbi Nadir prostate-specific antigen within 12 months after radiotherapy predicts biochemical and distant failure
    Michael E Ray
    Department of Radiation Oncology, University of Michigan Medical Center, Ann Arbor, Michigan 48109 0010, USA
    Urology 68:1257-62. 2006
    ..To determine whether nadir prostate-specific antigen (PSA) levels within 12 months (nadir PSA12) after completion of radiotherapy (RT) can be used as an early marker of recurrence risk...
  6. ncbi Percent positive biopsy cores as a prognostic factor for prostate cancer treated with external beam radiation
    Aaron C Spalding
    Department of Radiation Oncology, University of Michigan Medical School, Ann Arbor, Michigan 48109, USA
    Urology 69:936-40. 2007
    ..To examine the prognostic value of percent positive cores (PPC) in prostate cancer patients treated with external beam radiotherapy (RT)...
  7. ncbi Long-term outcomes after radiotherapy for retroperitoneal and deep truncal sarcoma
    Mary Feng
    Department of Radiation Oncology, University of Michigan Medical School, Ann Arbor, MI, USA
    Int J Radiat Oncol Biol Phys 69:103-10. 2007
    ..To determine the long-term outcomes after multimodality treatment of retroperitoneal, pelvic, and deep truncal sarcomas and to identify the factors associated with local control (LC), distant metastasis (DM), and overall survival (OS)...
  8. ncbi Inhibition of mTOR radiosensitizes soft tissue sarcoma and tumor vasculature
    James D Murphy
    Department of Radiation Oncology, University of Michigan, Ann Arbor, Michigan 48109 5010, USA
    Clin Cancer Res 15:589-96. 2009
    ..This study tested the hypothesis that rapamycin radiosensitizes soft tissue sarcoma and endothelial cells in vitro and in vivo through the inhibition of mTOR...
  9. ncbi No effect of statins on biochemical outcomes after radiotherapy for localized prostate cancer
    Daniel E Soto
    Department of Radiation Oncology, University of Michigan, Ann Arbor, Michigan, USA
    Urology 73:158-62. 2009
    ..To examine the effect of concurrent statin use during definitive radiotherapy (RT) on the biochemical outcomes for localized prostate cancer...
  10. ncbi Randomized phase II trial of urethral sparing intensity modulated radiation therapy in low-risk prostate cancer: implications for focal therapy
    Jeffrey Vainshtein
    Department of Radiation Oncology, University of Michigan Hospital, Ann Arbor, MI, USA
    Radiat Oncol 7:82. 2012
    ....
  11. ncbi Impact of common iliac nodal treatment on radiation outcomes in localized prostate cancer
    Daniel E Soto
    Department of Radiation Oncology, University of Michigan Medical School, Ann Arbor, Michigan 48109 0010, USA
    Urology 71:313-7. 2008
    ..We examined the effect of differences in the level of pelvic nodal coverage using three-dimensional conformal radiotherapy on biochemical failure-free survival (BFFS) and PFS in early-stage prostate cancer...
  12. ncbi Gemcitabine-mediated radiosensitization of human soft tissue sarcoma
    James D Murphy
    Department of Radiation Oncology, University of Michigan, Ann Arbor, MI, USA
    Transl Oncol 1:50-6. 2008
    ..The purpose of this study was to determine the radiosensitizing potential of gemcitabine in preclinical models of human STS...
  13. ncbi Targeted and systemic radiotherapy in the treatment of bone metastasis
    Alexander Lin
    Department of Radiation Oncology, University of Michigan, UHB2C490 1500 East Medical Center Drive, Ann Arbor, MI 48109 0010, USA
    Cancer Metastasis Rev 25:669-75. 2006
    ..Combined with appropriate medical and surgical interventions, as well as the appropriate use of analgesics, radiotherapy is a well-tolerated and highly effective treatment for the palliation of symptomatic bone metastases...
  14. ncbi Adjuvant therapy for soft tissue sarcoma
    Scott M Schuetze
    Department of Medicine, Division of Hematology Oncology, University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan, USA
    J Natl Compr Canc Netw 3:207-13. 2005
    ....
  15. ncbi Loss of Raf kinase inhibitory protein induces radioresistance in prostate cancer
    Kathleen M Woods Ignatoski
    Department of Urology, University of Michigan Health System, Ann Arbor, MI 48109 0940, USA
    Int J Radiat Oncol Biol Phys 72:153-60. 2008
    ..Chemotherapeutic agents have been shown to induce tumor apoptosis through induction of RKIP expression. Our goal was to test whether RT similarly induces apoptosis through induction of RKIP expression...
  16. ncbi Full-dose gemcitabine and concurrent radiotherapy for unresectable pancreatic cancer
    James D Murphy
    Department of Radiation Oncology, University of Michigan, Ann Arbor, MI 48109 0010, USA
    Int J Radiat Oncol Biol Phys 68:801-8. 2007
    ..This study was conducted to assess the pattern of failure and toxicity associated with the use of conformal treatment volumes, omitting prophylactic lymph node irradiation...
  17. ncbi Primary versus radiation-associated craniofacial osteosarcoma: Biologic and clinicopathologic comparisons
    Jonathan B McHugh
    Department of Pathology, University of Michigan, Ann Arbor, Michigan 48109-0054, USA
    Cancer 107:554-62. 2006
    ..In addition, they demonstrate higher expression rates of adverse prognostic indicators, further highlighting the distinction...
  18. ncbi Cochlear implantation with ipsilateral petroclival chondrosarcoma
    Erin M Lin
    Department of Otolaryngology, University of Michigan, Ann Arbor, Michigan 48109-0312, USA
    Otol Neurotol 27:337-41. 2006
    ..CONCLUSION: The implications of observing low-grade chondrosarcomas in well-selected patients and the unique aspect of cochlear implantation on the affected side are discussed...
  19. ncbi Radiation therapy for aggressive fibromatosis (desmoid tumor)
    Michael E Ray
    J Clin Oncol 24:3714-5; author reply 3715. 2006